Cargando…

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?

Despite advances in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and other common autoimmune neuropathies (AN), still-many patients with these diseases do not respond satisfactorily to the available treatments. Repurposing of disease-modifying therapies (DMTs) fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohle, Felix, Dalakas, Marinos C., Lehmann, Helmar C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810996/
https://www.ncbi.nlm.nih.gov/pubmed/36620728
http://dx.doi.org/10.1177/17562864221137129
_version_ 1784863433263415296
author Kohle, Felix
Dalakas, Marinos C.
Lehmann, Helmar C.
author_facet Kohle, Felix
Dalakas, Marinos C.
Lehmann, Helmar C.
author_sort Kohle, Felix
collection PubMed
description Despite advances in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and other common autoimmune neuropathies (AN), still-many patients with these diseases do not respond satisfactorily to the available treatments. Repurposing of disease-modifying therapies (DMTs) from other autoimmune conditions, particularly multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD), is a promising strategy that may accelerate the establishment of novel treatment choices for AN. This approach appears attractive due to homologies in the pathogenesis of these diseases and the extensive post-marketing experience that has been gathered from treating MS and NMOSD patients. The idea is also strengthened by a number of studies that explored the efficacy of DMTs in animal models of AN but also in some CIDP patients. We here review the available preclinical and clinical data of approved MS therapeutics in terms of their applicability to AN, especially CIDP. Promising therapeutic approaches appear to be B cell–directed and complement-targeting strategies, such as anti-CD20/anti-CD19 agents, Bruton’s tyrosine kinase inhibitors and anti-C5 agents, as they exert their effects in the periphery. This is a major advantage because, in contrast to MS, their action in the periphery is sufficient to exert significant immunomodulation.
format Online
Article
Text
id pubmed-9810996
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-98109962023-01-05 Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy? Kohle, Felix Dalakas, Marinos C. Lehmann, Helmar C. Ther Adv Neurol Disord Review Despite advances in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and other common autoimmune neuropathies (AN), still-many patients with these diseases do not respond satisfactorily to the available treatments. Repurposing of disease-modifying therapies (DMTs) from other autoimmune conditions, particularly multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD), is a promising strategy that may accelerate the establishment of novel treatment choices for AN. This approach appears attractive due to homologies in the pathogenesis of these diseases and the extensive post-marketing experience that has been gathered from treating MS and NMOSD patients. The idea is also strengthened by a number of studies that explored the efficacy of DMTs in animal models of AN but also in some CIDP patients. We here review the available preclinical and clinical data of approved MS therapeutics in terms of their applicability to AN, especially CIDP. Promising therapeutic approaches appear to be B cell–directed and complement-targeting strategies, such as anti-CD20/anti-CD19 agents, Bruton’s tyrosine kinase inhibitors and anti-C5 agents, as they exert their effects in the periphery. This is a major advantage because, in contrast to MS, their action in the periphery is sufficient to exert significant immunomodulation. SAGE Publications 2023-01-02 /pmc/articles/PMC9810996/ /pubmed/36620728 http://dx.doi.org/10.1177/17562864221137129 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Kohle, Felix
Dalakas, Marinos C.
Lehmann, Helmar C.
Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
title Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
title_full Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
title_fullStr Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
title_full_unstemmed Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
title_short Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
title_sort repurposing ms immunotherapies for cidp and other autoimmune neuropathies: unfulfilled promise or efficient strategy?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810996/
https://www.ncbi.nlm.nih.gov/pubmed/36620728
http://dx.doi.org/10.1177/17562864221137129
work_keys_str_mv AT kohlefelix repurposingmsimmunotherapiesforcidpandotherautoimmuneneuropathiesunfulfilledpromiseorefficientstrategy
AT dalakasmarinosc repurposingmsimmunotherapiesforcidpandotherautoimmuneneuropathiesunfulfilledpromiseorefficientstrategy
AT lehmannhelmarc repurposingmsimmunotherapiesforcidpandotherautoimmuneneuropathiesunfulfilledpromiseorefficientstrategy